表皮生长因子受体酪氨酸激酶抑制剂治疗可手术非小细胞肺癌的研究进展

Progress of epidermal growth factor receptor-tyrosine kinase inhibitors in treatment of operable non-small cell lung cancer

新辅助及辅助化疗对可手术非小细胞肺癌(NSCLC)5年生存率的提高非常有限。表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)在EGFR突变晚期NSCLC的治疗取得突破,为NSCLC患者围术期进行靶向治疗的探索带来希望。目前一代和三代EGFR-TKI在围术期患者中的靶向治疗研究已取得了显著进展,高效低毒的靶向治疗为可手术NSCLC带来了新的治疗手段。文章就EGFR突变NSCLC辅助及新辅助靶向治疗的进展及存在的问题进行综述。

Patients with operable non-small cell lung cancer(NSCLC)receiving neoadjuvant or adjuvant chemotherapy have a very limited improvement in 5-year survival rate.Epidermal growth factor receptor-tyrosine kinase inhibitors(ECFR-TKI)have made a breakthrough in the treatment of EGFR-mutant advanced NSCLC,which shed light for the exploration of perioperative targeted therapy in NSCLC patients.Significant progress has been made in the research of targeted therapy of the first and third generation EGFRTKI in perioperative patients.The availability of novel potent and less toxic targeted therapy has brought new treatments for the operable NSCLC.This article reviews the progress and existing problems of adjuvant and neoadjuvant targeted therapy in NSCLC harboring EGFR mutation.